Article Figures & Tables
Tables
Category Patented Medicine Prices Review Board Prescrire International† Major therapeutic gain Breakthrough
Substantial improvementBravo
A real advanceModerate therapeutic gain Moderate (primary or secondary) Offers an advantage Little to no therapeutic gain Slight or no improvement Possibly helpful
Nothing new
Not acceptable*Ratings from the 2 organizations were grouped to make them comparable in terms of their assessment of the new therapeutic value offered.
†The Prescrire category "judgment reserved" was not used.
Category Year; no. (%) of drugs 2013* 2014† 2015‡ Most-promoted drugs
n = 28Top-selling drugs
n = 30Most-promoted drugs
n = 29Top-selling drugs
n = 29Most-promoted drugs
n = 32Top-selling drugs
n = 29Major therapeutic gain 0 (0) 5 (17) 1 (3) 4 (14) 1 (3) 4 (14) Moderate therapeutic gain 1 (4) 2 (7) 2 (7) 2 (7) 2 (6) 2 (7) Little to no therapeutic gain 27 (96) 23 (77) 26 (90) 23 (79) 29 (91) 23 (79) *p = 0.04, Fisher exact test.
†p = 0.4, Fisher exact test.
‡p = 0.4, Fisher exact test.
- Table 3: Amount spent on journal advertising and sales representative visits by therapeutic value
Category Year; amount spent, $ thousands (% of total) 2013 2014 2015 Major therapeutic gain 0 (0.0) 3711 (2.3) 3359 (1.6) Moderate therapeutic gain 5816 (3.5) 9350 (5.7) 9268 (4.5) Little to no therapeutic gain 159 999 (96.5) 149 941 (92.0) 192 644 (93.8) Overall 165 815 (100.0) 163 002 (100.0) 205 271 (100.0)